Image Place holder

Aixa E. Soyano, MD


Specialty: Hematology/Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Aixa Soyano is an Assistant Member in the Department of Breast Oncology. Dr. Soyano received her MD degree from Universidad Central de Venezuela/Escuela de Medicina in Venezuela. She completed an Internal Medicine Residency at Steward Saint Elizabeth’s Medical Center in Boston, Massachusetts. Dr. Soyano recently completed a Hematology Oncology Fellowship at Mayo Clinic in Jacksonville, Florida. Dr. Soyano is interested in the multidisciplinary care of patients of any age and race with breast cancer of any stage and subtype. Her research interest is in the future of oncology related to personalized medicine.

Education & Training

Fellowship:

  • Mayo Clinic - Hematology Oncology

Residency:

  • Steward Saint Elizabeth’s Medical Center - Internal Medicine

Medical School:

  • Universidad Central de Venezuela - MD
Participating Trials

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18810
Phase 1b Study To Assess The Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole Or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (Mbc)
Condition: Breast
Intervention: 772256 (Palbociclib); Faslodex (fulvestrant); Femara (Letrozole); Gedatolisib; Letrozole; PF-05212384 (Gedatolisib); Palbociclib; fulvestrant
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 19603
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); SGN-LIV1A
Open

CLINICAL TRIAL 18979
Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19755
A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination with Intravenous Pembrolizumab Therapy in Patients with Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); tavo-EP
Open

CLINICAL TRIAL 19803
A Phase II Trial With Safety Run-In Of Neoadjuvant Therapy With An Aromatase Inhibitor In Combination With Durvalumab (Medi4736) In Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
Condition: Breast
Intervention: AMP-514 (Durvalumab); Anastrozole; Arimadex (Anastrozole); Aromasin (Exemestane); Durvalumab; Exemestane; Femara (Letrozole); Letrozole; MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 19394
An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2-Negative, Brca-Mutant Breast Cancer Patients
Condition: Breast
Intervention: Niraparib
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Lou Y, Marin-Acevedo JA, Vishnu P, Manochakian R, Dholaria B, Soyano A, Luo Y, Zhang Y, Knutson KL. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy. 2019 May;11(7):577-584. Pubmedid: 30943864.
  • Soyano AE, Baldeo C, Kasi PM. Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence. Front Oncol. 2019 Feb;9:46. Pubmedid: 30788289. Pmcid: PMC6372543.
  • Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano A, Mashadi-Hossein A, Warren SE, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clin Cancer Res. 2019 Feb. Pubmedid: 30808774.
  • Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, Ko SJ, Thomas M, Johnson MM, Patel NM, Miller RC, Adjei AA, Ailawadhi S. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018 Oct;7(10):4932-4942. Pubmedid: 30175515. Pmcid: PMC6198232.
  • Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018 Mar;11(1):39. Pubmedid: 29544515. Pmcid: PMC5856308.
  • Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan;11(1):8. Pubmedid: 29329556. Pmcid: PMC5767051.
  • Soyano AE, Baldeo C, Kasi PM. BRCA Mutation and Its Association With Colorectal Cancer. Clin Colorectal Cancer. 2018 Dec;17(4):e647-e650. Pubmedid: 30033118.
  • Dholaria BR, Hammond WA, Roy V, Sher T, Vishnu P, Soyano A, Finn LE, Tun H. Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. Leuk Lymphoma. 2018 11;59(11):2727-2730. Pubmedid: 29566563.
  • Soyano AE, Kassi M, Kasi PM. Neuroendocrine Tumor Involving the Epicardium. Case Rep Oncol. 10(3):1144-1149. Pubmedid: 29430241. Pmcid: PMC5803682.